We are pleased to hear that Johan Hyllner has been recruited to AstraZeneca as Head of their Cell and Gene Therapy program.
This is great news for Sweden, AstraZeneca and CAMP and follows last years announcement that Johan would leave his position at Catapult UK as the Chief Scientific Officer. Johan will be working from the AstraZeneca R&D site in Gothenburg, Sweden.
The recruitment of Johan is another demonstration of AstraZeneca’s strategic commitment to novel therapeutics through ATMP programs. The company is pursuing ATMP programs in their Cardiovascular, Renal and Metabolism disease areas, including the collaboration with the Swedish company Procella Therapeutics, developing cardiac cell types from pluripotent stem cells.
AstraZeneca are partners in both CAMP and Swelife-ATMP.